India’s Laurus Labs Ltd. says it is expanding its current capacities for key active pharmaceutical ingredients to meet increasing demand for third-party API sales, after the company saw an “extraordinary year” as it reported a 70% year on year jump in revenues to INR48.14bn ($652m) for its financial year ended 31 March 2021.
As Laurus registered a sales increase of INR19.81bn in a single financial year, founder and CEO Satyanarayana Chava also stated that the company is seeing many new opportunities in developed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?